Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TAK-573 |
Synonyms | |
Therapy Description |
TAK-573 is a fusion of an anti-CD38 antibody and attenuated IFN-alpha, which potentially inhibits tumor growth (Clinical Lymphoma, Myeloma and Leukemia, Volume 19, Issue 10, e116). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TAK-573 | TAK 573|TEV-48573|TAK573|TEV48573|TEV-48573|Modakafusp Alfa | CD38 Antibody 20 | TAK-573 is a fusion of an anti-CD38 antibody and attenuated IFN-alpha, which potentially inhibits tumor growth (Clinical Lymphoma, Myeloma and Leukemia, Volume 19, Issue 10, e116). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04157517 | Phase I | TAK-573 | A Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics Study | Completed | USA | AUS | 0 |
NCT03215030 | Phase Ib/II | Dexamethasone + TAK-573 TAK-573 | A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma (MM) | Active, not recruiting | USA | TUR | NOR | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CAN | 5 |